+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Therapeutics Market - Global Forecast 2026-2032- Product Image
Gout Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Gout Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904565
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gout therapeutics market is rapidly evolving, presenting new opportunities and challenges for industry leaders navigating innovation in clinical practice and commercial operations. Ongoing advancements across therapy modalities, care models, and regulatory frameworks are reshaping how decision-makers manage growth, access, and risk within this dynamic landscape.

Market Snapshot: Gout Therapeutics Market Growth and Outlook

The gout therapeutics market expanded from USD 3.40 billion in 2025 to USD 3.78 billion in 2026 and is expected to reach USD 7.58 billion by 2032, registering a CAGR of 12.13%. Market growth is driven by innovation in biologic and precision therapies, greater adoption of patient-centric models, and restructured distribution channels in leading healthcare regions. Decision-makers are observing a shift in the landscape as new therapy modalities, regulatory complexity, and evolving patient access pathways set the stage for sustained transformation and competitive positioning.

Scope & Segmentation Analysis

This report provides comprehensive coverage for B2B stakeholders by detailing pivotal market segments, therapeutic advancements, and geographic diversity shaping the gout therapeutics sector:

  • Administration Routes: Encompasses oral, intravenous, and subcutaneous products, each influencing clinical flexibility and facilitating divergent care delivery options.
  • Therapy Lines: Evaluates first-line, second-line, and third-line treatments, addressing individual patient needs such as comorbid conditions, prior treatment outcomes, and flare characteristics.
  • Drug Classes: Covers nonsteroidal anti-inflammatory agents, xanthine oxidase inhibitors, uricosuric agents, corticosteroids, and uricase-based biologics, each optimized for specific clinical scenarios within the spectrum of gout management.
  • Distribution Channels: Reviews reach and patient access through inpatient and outpatient hospital pharmacies, retail outlets, specialty pharmacy providers, and emerging online models, emphasizing the importance of logistical strategies.
  • Geographic Coverage: Profiles regional variations and dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific, underscoring the influence of regulatory practices, payer protocols, and healthcare delivery systems.
  • Innovative Modalities: Highlights market disruption through advanced biologics, expanded subcutaneous delivery options, and digital therapeutics that support personalized approaches and heightened patient engagement.

Key Strategic Takeaways for Decision-Makers

  • Personalized medicine is advancing in gout treatment as biologics and enzymatic therapies enable targeted patient stratification and improved clinical outcomes.
  • Manufacturers are proactively bolstering supply chain resilience by diversifying vendor relationships and exploring localization strategies to mitigate procurement uncertainties.
  • Introduction of subcutaneous and remote self-administration formulations increases adherence rates and reduces dependence on facility-based interventions.
  • Growing payer scrutiny is accelerating the adoption of value-based contracts and engagement models, requiring coordinated response from manufacturers and providers.
  • Distinct regional factors—including regulatory timelines, system capacity, and healthcare funding—necessitate tailored approaches to go-to-market strategy and access optimization.

Impact of United States Tariff Policy Changes in 2025

Impending changes to U.S. tariff policy introduce significant complexity to pharmaceutical supply chains and price structures. Higher import duties on pharmaceuticals, excipients, and packaging—especially those associated with biologics—are anticipated to increase manufacturing costs across the sector. In response, manufacturers are reassessing supplier selection, exploring nearshoring opportunities, and adjusting operational practices to protect profitability and ensure continuous product availability. Concurrently, payer organizations and healthcare providers are intensifying their emphasis on value-driven care, revising approval processes, and revisiting therapy adoption protocols. Companies with global supply dependencies are advised to enhance risk management and closely monitor regulatory developments in order to maintain operational agility.

Methodology & Data Sources

Research findings are compiled through direct interviews with clinical, payer, pharmacy, and manufacturing experts, and further validated by reviewing recent clinical data, practice guidelines, and supply chain information. This triangulated research methodology offers a reliable foundation for strategic direction and operational alignment.

Why This Report Matters to Industry Leaders

  • Offers timely intelligence on evolving clinical trends, payer responses, and shifting market forces to guide informed, organization-wide decision-making.
  • Delivers actionable frameworks for commercial, regulatory, and operational teams to strengthen positioning and minimize exposure to global market pressures.
  • Facilitates evidence-led planning for formulary inclusion, price negotiations, and patient support initiatives across varied geographies and healthcare systems.

Conclusion

Long-term growth in the gout therapeutics market will depend on integrated, cross-functional strategies that unite scientific, operational, and commercial priorities. Organizations aligning their objectives in this way will best capture the evolving set of opportunities.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gout Therapeutics Market, by Route Of Administration
8.1. Injectable
8.1.1. Intravenous
8.1.2. Subcutaneous
8.2. Oral
9. Gout Therapeutics Market, by Therapy Line
9.1. First Line
9.1.1. Nonsteroidal Anti-Inflammatory Drug
9.1.1.1. Ibuprofen
9.1.1.2. Indomethacin
9.1.1.3. Naproxen
9.1.2. Xanthine Oxidase Inhibitor
9.1.2.1. Allopurinol
9.1.2.2. Febuxostat
9.2. Second Line
9.2.1. Colchicine
9.2.2. Uricosuric Agent
9.2.2.1. Benzbromarone
9.2.2.2. Lesinurad
9.2.2.3. Probenecid
9.3. Third Line
9.3.1. Corticosteroid
9.3.1.1. Methylprednisolone
9.3.1.2. Prednisone
9.3.2. Uricase Agent
9.3.2.1. Pegloticase
9.3.2.2. Rasburicase
10. Gout Therapeutics Market, by Drug Class
10.1. Anti-Inflammatory Agent
10.1.1. Colchicine
10.1.2. Corticosteroid
10.2. Uricase Agent
10.2.1. Pegloticase
10.2.2. Rasburicase
10.3. Uricosuric Agent
10.3.1. Benzbromarone
10.3.2. Lesinurad
10.3.3. Probenecid
10.4. Xanthine Oxidase Inhibitor
10.4.1. Allopurinol
10.4.2. Febuxostat
10.4.3. Topiroxostat
11. Gout Therapeutics Market, by Distribution Channel
11.1. Hospital Pharmacy
11.1.1. Inpatient Pharmacy
11.1.2. Outpatient Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Gout Therapeutics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Gout Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Gout Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Gout Therapeutics Market
16. China Gout Therapeutics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. Amgen Inc.
17.7. Arthrosi Therapeutics, Ltd.
17.8. AstraZeneca plc
17.9. Atom Therapeutics Co., Ltd.
17.10. Boehringer Ingelheim International GmbH
17.11. Dr. Reddy’s Laboratories Ltd.
17.12. Eli Lilly and Company
17.13. GlaxoSmithKline plc
17.14. Horizon Therapeutics plc
17.15. Ironwood Pharmaceuticals, Inc.
17.16. Merck & Co., Inc.
17.17. Novartis AG
17.18. Olatec Therapeutics LLC
17.19. Pfizer Inc.
17.20. Protalix BioTherapeutics, Inc.
17.21. Regeneron Pharmaceuticals, Inc.
17.22. Selecta Biosciences, Inc.
17.23. Sobi
17.24. Sun Pharmaceutical Industries Ltd.
17.25. Synlogic, Inc.
17.26. Takeda Pharmaceutical Company Limited
17.27. Teijin Pharma Limited
17.28. Teva Pharmaceutical Industries Ltd.
17.29. Urica Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 158. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 159. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 160. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 161. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 162. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 163. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 164. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 165. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 167. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 168. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 169. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 170. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 177. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 178. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 179. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 180. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 181. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 182. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 183. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 184. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 185. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 186. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 187. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 188. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 189. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 192. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 194. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 195. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 196. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 197. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 198. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 199. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 200. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 201. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 202. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 203. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 204. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 205. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 206. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 207. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 208. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 229. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 230. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 231. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 232. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 233. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 234. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 235. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 236. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 237. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 238. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 239. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 240. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 241. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 243. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 244. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 245. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 246. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. EUROPE GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 251. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 252. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 256. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 257. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 258. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 259. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 260. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 261. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 262. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 263. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 264. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 265. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. MIDDLE EAST GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 267. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 269. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 270. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 271. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 272. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 273. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 274. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 275. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 276. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 277. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 278. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 279. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 280. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 281. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 282. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 283. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 284. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 285. AFRICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 286. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 287. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 288. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 289. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 290. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 291. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 292. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 293. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 294. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 295. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 296. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 297. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 298. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 299. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 300. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 301. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 302. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 303. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 305. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 306. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 307. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 308. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 309. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
TABLE 310. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 311. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2032 (USD MILLION)
TABLE 312. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 313. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 314. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 315. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2032 (USD MILLION)
TABLE 316. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2032 (USD MILLION)
TABLE 317. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 318. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 319. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2032 (USD MILLION)
TABLE 320. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2032 (USD MILLION)
TABLE 321. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2032 (USD MILLION)
TABLE 322. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2032 (USD MILLION)
TABLE 323. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 324. ASEAN GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
TABLE 325. GCC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 326. GCC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 327. GCC GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 328. GCC GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
T

Companies Mentioned

The key companies profiled in this Gout Therapeutics market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Arthrosi Therapeutics, Ltd.
  • AstraZeneca plc
  • Atom Therapeutics Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Ironwood Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Selecta Biosciences, Inc.
  • Sobi
  • Sun Pharmaceutical Industries Ltd.
  • Synlogic, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • Teva Pharmaceutical Industries Ltd.
  • Urica Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.78 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.58 Billion
Compound Annual Growth Rate12.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Gout Medications Market - Global Forecast 2026-2032 - Product Image

Gout Medications Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Gout Therapeutics Market Report 2025 - Product Image

Gout Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Gout Therapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Gout Therapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From
Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030 - Product Image

Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

  • Report
  • 180 Pages
  • Global
From

About the Gout Drug Market

The Gout Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Gout drugs are used to reduce the inflammation and pain associated with gout, a type of arthritis caused by the buildup of uric acid in the joints. These drugs can be taken orally or injected directly into the affected joint. Commonly prescribed gout drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Gout drugs are typically prescribed by a doctor and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the form in which it is taken. Some companies in the Gout Drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.